4.75
6.86%
-0.35
After Hours:
4.72
-0.03
-0.63%
Aptorum Group Ltd stock is currently priced at $4.75, with a 24-hour trading volume of 24,399.
It has seen a -6.86% decreased in the last 24 hours and a -34.48% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.00 pivot point. If it approaches the $4.69 support level, significant changes may occur.
Previous Close:
$5.10
Open:
$5.13
24h Volume:
24,399
Market Cap:
$25.99M
Revenue:
$1.20M
Net Income/Loss:
$-13.40M
P/E Ratio:
-1.7486
EPS:
-2.7164
Net Cash Flow:
$-11.64M
1W Performance:
-4.81%
1M Performance:
-34.48%
6M Performance:
+182.74%
1Y Performance:
+30.14%
Aptorum Group Ltd Stock (APM) Company Profile
Name
Aptorum Group Ltd
Sector
Industry
Phone
44 20 8092 9299
Address
17 Hanover Square, London
Aptorum Group Ltd Stock (APM) Latest News
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update - 30.04.2024 - wallstreet:online
wallstreet:online
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
US Stocks Higher; Producer Prices Rise 0.6% In February
Benzinga
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales
Benzinga
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga
Aptorum Group Ltd Stock (APM) Financials Data
Aptorum Group Ltd (APM) Revenue 2024
APM reported a revenue (TTM) of $1.20 million for the quarter ending June 30, 2023, a -1.82% decline year-over-year.
Aptorum Group Ltd (APM) Net Income 2024
APM net income (TTM) was -$13.40 million for the quarter ending June 30, 2023, a -376.92% decrease year-over-year.
Aptorum Group Ltd (APM) Cash Flow 2024
APM recorded a free cash flow (TTM) of -$11.64 million for the quarter ending June 30, 2023, a +26.24% increase year-over-year.
Aptorum Group Ltd (APM) Earnings per Share 2024
APM earnings per share (TTM) was -$3.65 for the quarter ending June 30, 2023, a -508.33% decline year-over-year.
About Aptorum Group Ltd
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):